#ASCOGU25
🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TWMP3N !

#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
November 17, 2026 at 8:58 AM
🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TWF1j0 !

#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
November 7, 2026 at 7:05 PM
🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TW6F2g !

#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
October 29, 2026 at 3:58 PM
🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TW6F2g !

#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
October 29, 2026 at 3:58 PM
🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TVznkr !

#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
October 20, 2026 at 9:19 AM
🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TVsc9b !

#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
October 11, 2026 at 7:58 AM
🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TVkgfk !

#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
October 1, 2026 at 6:05 PM
🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TVbXz1 !

#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view
dlvr.it
September 22, 2026 at 2:58 PM
🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TVSKnB !

#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view
dlvr.it
September 13, 2026 at 9:19 AM
🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TVKFR6 !

#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view
dlvr.it
September 4, 2026 at 7:59 AM
🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TV9VQq !

#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
August 25, 2026 at 6:05 PM
=>2L at #O3B trial in #RCC #ASCOGU25. Would you try the new anti-CTLA4 (Quavonlimab) in anti-CTLA4-naive pts?
PEM/Q vs PEM/Len.
ORR: 30% vs 40%.
1yPFS: 39% vs 34%.
1yOS 75% vs 82%.
TRAE: 25% vs 49%
irAE: 20% vs 44% (only 5% G3+)
Treatment every 6 weeks.
@rickyfrazer1.bsky.social
April 6, 2025 at 12:33 PM
Looking forward to #ASCOGU25
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca

@rickyfrazer1.bsky.social @jmcgrane.bsky.social
February 10, 2025 at 12:46 AM
Looking forward to watching sessions virtually and following updates. But, as a Canadian, I will not be attending any meetings in the USA until this utter nonsense against our country stops. #ASCOGU25
February 13, 2025 at 2:37 PM
🚀 Excited for #ASCOGU25! Looking forward to groundbreaking insights and game-changers once again! 🔬 Can't wait to see what’s ahead. 🎯 Stay tuned! #UroOncology #GameChanger
@axelmerseburger.bsky.social
February 8, 2025 at 2:38 PM
Most men with advanced #ProstateCancer benefit from new-generation drugs targeting the androgen receptor (ARPIs), but older patients may benefit from some ARPIs more than others.

These results from the STOPCAP meta-analysis were presented at #ASCOGU25 by @dfishstats.bsky.social.
STOPCAP study finds that most men with advanced prostate cancer benefit from new-generation hormone therapy drugs | MRC Clinical Trials Unit at UCL
13 Feb 2025
buff.ly
February 13, 2025 at 6:03 PM
🚀 Who are the top oncologists leading the digital conversation?

📢 Check out this ranking of digital thought leaders in oncology based on their Twitter following!

📊 Notably, female oncologists highlighted in green! 👇 #GU25 #ASCOGU25
February 5, 2025 at 1:20 PM
Heading to #ASCOGU25? Click the link below for a list of @danafarber.bsky.social presentations from the ASCO GU Symposium, the leading specialized research and education meeting for GU cancer care. âž¡️https://bit.ly/4gI3DFm
Dana-Farber at #ASCOGU25
ASCO GU Symposium is the leading specialized research and education meeting for GU cancer care.
bit.ly
February 10, 2025 at 5:30 PM
Excited for all going to #ASCOGU25 this year. As a patient and advocate I enjoy seeing what researchers and doctors get excited about from their standpoint.

An Informed patient is an empowered patient.

#Cansky #Oncsky #Medsky #ASCO #GU25
February 13, 2025 at 2:30 PM
Honored to present CABOLD study design at #ASCOGU25!
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo

#ASCOGU25 #KidneyCancer #OncoGeriatrics
February 15, 2025 at 11:23 PM
Puerto Rico was incredible, snuck a quick trip to San Francisco for a #ASCOGU25 meeting & back to NOLA next wk for #MardiGras. I always think it’s funny that the pic on the left is the reality of my life just as much as the pic on the right. I’ve lived many different versions of myself this month.
February 16, 2025 at 1:15 AM
On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily.bsky.social @oncoalert.bsky.social
February 15, 2025 at 5:23 PM